In: Obesity
Trials
19 active
32 in total · 7 in the EU
What this is
- How it works
- Copies GLP-1, a gut hormone that lowers appetite and blood sugar, and blocks the receptor for GIP, another gut hormone.GLP-1 agonist + GIPR antagonist antibody
- How it’s given
- “Participants will receive maridebart cafraglutide as SC injections.”In the company’s words, NCT07225686 on ClinicalTrials.gov
- Tested for
- Obesity (11 trials), Overweight (8 trials), Obstructive Sleep Apnea (2 trials), Diabetes Mellitus, Type 2 (2 trials), Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Obesity Disease, Obesity or Overweight, Heart Failure With Preserved Ejection Fraction and 5 more
- Main trialPhase 3
- “The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.”In the company’s words, NCT06858878 on ClinicalTrials.gov
- Other names
- MariTide · AMG 133
Other drugs for Obesity
- CagriSemaNovo Nordisk · Filed (US)
- HRS-7535Hengrui · Kailera · Filed (China)
- RibupatideHengrui · Kailera · Filed (China)
- RetatrutideEli Lilly · Phase 3
- IN-B00009HK inno.N · Phase 3
- UBT251United Laboratories · Novo Nordisk · Phase 3
Coming up12
- 18 NovPhase 1 trial completes · ClinicalTrials.gov
- 21 Jan 2027Phase 3 trial completes · ClinicalTrials.gov
- 21 Jan 2027Phase 3 trial completes · ClinicalTrials.gov
- 23 Mar 2027Phase 1 trial completes · ClinicalTrials.gov
- 27 Apr 2027Phase 3 trial completes · ClinicalTrials.gov
- 16 Jun 2027Phase 3 trial completes · ClinicalTrials.gov
- 26 Jul 2027Phase 1 trial completes · ClinicalTrials.gov
- 20 Aug 2027Phase 3 trial completes · ClinicalTrials.gov
- 25 Aug 2027Phase 2 trial completes · ClinicalTrials.gov
- 30 Aug 2027Phase 3 trial completes · ClinicalTrials.gov
- 20 Dec 2027Phase 1 trial completes · ClinicalTrials.gov
- 26 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 9 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT07871409
Trials32
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 21 Jan 2027 | Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | |
| Phase 3Active, not recruiting | 21 Jan 2027 | Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | |
| Phase 3Active, not recruiting | 27 Apr 2027 | Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease | |
| Phase 3Recruiting | 16 Jun 2027 | Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight | |
| Phase 3Active, not recruiting | 20 Aug 2027 | Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | |
| Phase 3Active, not recruiting | 30 Aug 2027 | Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | |
| Phase 3Recruiting | 26 Dec 2027 | Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION) | |
| Phase 3Recruiting | 26 Dec 2027 | Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) | |
| Phase 3Recruiting | 3 Jan 2028 | Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH) | |
| Phase 3Recruiting | 30 Jun 2028 | Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | |
| Phase 3Active, not recruiting | 30 Jun 2028 | Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | |
| Phase 3Recruiting | 6 Sep 2028 | Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes | |
| Phase 2Active, not recruiting | 6 Oct 2025 | A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM) | |
| Phase 2Active, not recruiting | 25 Aug 2027 | A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight | |
| Phase 1Active, not recruiting | 15 Nov 2026 | A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus | |
| Phase 1Active, not recruiting | 18 Nov 2026 | Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity | |
| Phase 1Not yet recruiting | 23 Mar 2027 | Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous Dose | |
| Phase 1Not yet recruiting | 26 Jul 2027 | Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple Doses | |
| Phase 1Recruiting | 20 Dec 2027 | Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) | |
| Phase 2Completed | 8 Oct 2024 | Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus | |
| Phase 1Completed | 8 Apr 2022 | Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants | |
| Phase 1Completed | 18 Nov 2022 | Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity | |
| Phase 1Completed | 27 Aug 2024 | A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight | |
| Phase 1Completed | 27 Dec 2024 | A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity | |
| Phase 1Completed | 9 May 2025 | A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obesity | |
| Phase 1Completed | 22 May 2025 | A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or Obesity | |
| Phase 1Completed | 21 Nov 2025 | A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body | |
| Phase 1Completed | 26 Nov 2025 | The Effect of AMG 133 on Gastric Emptying | |
| Phase 1Completed | 26 Feb 2026 | A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function | |
| Phase 1Completed | 28 May 2026 | Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations | |
| Phase 1Completed | 2 Jul 2026 | A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations | |
| Phase 1Completed | 27 Aug 2026 | Effect of Maridebart Cafraglutide on the Heart's Electrical Activity |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026